Genentech Articles
Genentech's Avastin misses Ph III endpoint
3 July 2006
Japan stock week to June 5
12 June 2006
GSK's Tykerb 'to rival Herceptin,' Ph III study
12 June 2006
Stock Commentary - New York week to May 29, 2006
5 June 2006
Genentech submits Avastin sBLA to US FDA
5 June 2006
Roche's Herceptin OK for early use in EU, CHMP
29 May 2006
Genentech hires two new VPs
22 May 2006
Genentech boosts Curis R&D hedgehog effort
15 May 2006
BI's 1st-qtr revenues hit $611M, up 4%
8 May 2006
Three patent cases go to US Supreme Court
8 May 2006
Roche's 1st-qtr 2006 sales rise 22%
8 May 2006
Genentech extends stock repurchase plan
1 May 2006
Four vice president appointments at Genentech
17 April 2006
Genentech submits Avastin NSCLC sBLA
17 April 2006
Pfizer to purchase Rinat Neuroscience
17 April 2006
Good animal data for TopoTarget/Curagen's PXD101
10 April 2006
Genentech/Biogen Idec submit Rituxan sBLA
3 April 2006
Genentech to acquire OrigGener TrueClone Collection
3 April 2006
Stock Commentary - New York week to Mar 20, 2006
27 March 2006
Xoma reports strong growth in 2005
20 March 2006
Novartis seeks EU approval for Lucentis
13 March 2006
Pfizer/OSI's Macugen gets OK in Europe
27 February 2006
Stock Commentary - New York week to Feb 20, 2006
27 February 2006
Biogen Idec sees 8% 4th-qtr 2005 sales rise
27 February 2006
US FDA accepts NDAs from Genentech, Eisai, GSK and S-P
20 February 2006
Stock Commentary - New York week to Feb 13, 2006
20 February 2006
FDA approves Rituxan for NH lymphoma
20 February 2006
Lonza licenses GS System to Genentech
20 February 2006
OSI's Tarceva earns $25.0M in 4th-qtr 2005
13 February 2006
Amgen and Genentech deal on antibody patents
30 January 2006
US cancer therapy market to grow 10% pa through 2009
30 January 2006
Slew of promotions/appointments at Genentech
16 January 2006
FDA fast-tracks Favrille's FavId
16 January 2006
Kosan's KOS-953 plus Herceptin to enter Ph II
19 December 2005
Strong data for metronomic chemo
19 December 2005
Herceptin for early-stage use in Australia soon?
19 December 2005
Licensing pivotal to pharma industry evolving strategies
19 December 2005
Stock Commentary - New York week to Dec 5
12 December 2005
Novartis to set up French biotech center
12 December 2005
OXiGENE to initiate Ph Ib trial of CA4P combo
12 December 2005
SPECTRUM week to Nov 28
5 December 2005
25 years ago this week....
5 December 2005
GlobeImmune raises over $34M
19 September 2005
Tentative FDA OK for OSI/Genentech's Tarceva
19 September 2005
Genentech's Lucentis denied fast-track status
19 September 2005
Roche's MabThera filed in Europe as an RA drug
12 September 2005
Japan stock market two week to August 29
5 September 2005
Protein test may aid advanced cancer therapy
5 September 2005
Roche and partners apply for expanded indication for Rituxan
22 August 2005
Ian Clark promoted at Genentech
22 August 2005
Stock Commentary - New York
15 August 2005
Biogen Idec's second-quarter EPS rises 26%
15 August 2005
Genentech awards grants for Bay area
8 August 2005
EU nod for Novartis' Xolair in asthma
8 August 2005
Stock Commentary - New York
1 August 2005
Genentech buys rights to ImmunoGen' cancer drug
1 August 2005
Genentech warns on Raptiva risk
1 August 2005
Canadian provinces OK Genentech's Herceptin
1 August 2005
UPDATE: UK NICE fast-track of Herceptin welcomed
1 August 2005
UK fast-tracks Velcade, Herceptin through NICE
25 July 2005
Roche Rx sales grow three times world rate
25 July 2005
Tarceva approved in Canada for lung cancer
25 July 2005
BI and Genentech terminate TNKase/Metalyse trial
18 July 2005
Genentech to offer up to $2B notes
18 July 2005
OSI files sNDA on Tarceva with US FDA
18 July 2005
Genentech announces three appointments
11 July 2005
Genentech's Avastin: good AE profile
27 June 2005
Genentech extends share repurchase program
20 June 2005
Encouraging data for MabThera in RA
20 June 2005
Exelixis and Genentech enter R&D accord
13 June 2005
Exelixis and Genentech enter R&D accord
13 June 2005
Stock Commentary - Europe
6 June 2005
Stock Commentary - New York
6 June 2005
Tercica moves to block Insmed growth drug in USA
6 June 2005
Favrille's FavId Ph III enrollment on schedule
6 June 2005
Tercica prevails in UK court ruling
30 May 2005
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
